76 related articles for article (PubMed ID: 12760308)
1. Steroid and xenobiotic receptor (SXR) is a key system for the acquisition of cisplatin resistance in endometrial cancer cells.
Takami N; Sakamoto H; Yamamoto T
J Int Med Res; 2003; 31(2):59-68. PubMed ID: 12760308
[TBL] [Abstract][Full Text] [Related]
2. Emodin Enhances the Chemosensitivity of Endometrial Cancer by Inhibiting ROS-Mediated Cisplatin-resistance.
Ding N; Zhang H; Su S; Ding Y; Yu X; Tang Y; Wang Q; Liu P
Anticancer Agents Med Chem; 2018; 18(7):1054-1063. PubMed ID: 29256357
[TBL] [Abstract][Full Text] [Related]
3. The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition.
Fukuda T; Oda K; Wada-Hiraike O; Sone K; Inaba K; Ikeda Y; Miyasaka A; Kashiyama T; Tanikawa M; Arimoto T; Kuramoto H; Yano T; Kawana K; Osuga Y; Fujii T
Gynecol Oncol; 2015 Jun; 137(3):538-45. PubMed ID: 25842161
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin increases B-cell-lymphoma-2 expression via activation of protein kinase C and Akt2 in endometrial cancer cells.
Rouette A; Parent S; Girouard J; Leblanc V; Asselin E
Int J Cancer; 2012 Apr; 130(8):1755-67. PubMed ID: 21618512
[TBL] [Abstract][Full Text] [Related]
5. Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells.
Zhang X; Kyo S; Nakamura M; Mizumoto Y; Maida Y; Bono Y; Takakura M; Fujiwara H
Cancer Lett; 2014 Apr; 345(1):106-14. PubMed ID: 24333732
[TBL] [Abstract][Full Text] [Related]
6. Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure.
Sagawa Y; Fujitoh A; Nishi H; Ito H; Yudate T; Isaka K
Tumour Biol; 2011 Apr; 32(2):399-408. PubMed ID: 21113744
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells.
Basseville A; Preisser L; de Carné Trécesson S; Boisdron-Celle M; Gamelin E; Coqueret O; Morel A
Mol Cancer; 2011 Jul; 10():80. PubMed ID: 21733184
[TBL] [Abstract][Full Text] [Related]
8. Interaction of silencing mediator for retinoid and thyroid receptors with steroid and xenobiotic receptor on multidrug resistance 1 promoter.
Hirooka-Masui K; Lesmana R; Iwasaki T; Xu M; Hayasaka K; Haraguchi M; Takeshita A; Shimokawa N; Yamamoto K; Koibuchi N
Life Sci; 2013 May; 92(17-19):911-5. PubMed ID: 23562850
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor increases CD133 expression and progenitor-like population that associate with cisplatin resistance in endometrial cancer cell line.
Chen L; Chang WC; Hung YC; Chang YY; Bao BY; Huang HC; Chung WM; Shyr CR; Ma WL
Reprod Sci; 2014 Mar; 21(3):386-94. PubMed ID: 23962788
[TBL] [Abstract][Full Text] [Related]
10. [Study of claudin-4 in the diagnosis and treatment of endometrial carcinoma].
Pan XY; Li X; Che YC; Li X; Zhang Y
Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):768-71. PubMed ID: 24406135
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
Xu Y; Tong J; Ai Z; Wang J; Teng Y
J Obstet Gynaecol Res; 2012 Dec; 38(12):1358-66. PubMed ID: 22612393
[TBL] [Abstract][Full Text] [Related]
12. The endocrine disrupting chemical, diethylhexyl phthalate, activates MDR1 gene expression in human colon cancer LS174T cells.
Takeshita A; Inagaki K; Igarashi-Migitaka J; Ozawa Y; Koibuchi N
J Endocrinol; 2006 Sep; 190(3):897-902. PubMed ID: 17003290
[TBL] [Abstract][Full Text] [Related]
13. A novel mechanism for acquired cisplatin-resistance: suppressed translation of death-associated protein kinase mRNA is insensitive to 5-aza-2'-deoxycitidine and trichostatin in cisplatin-resistant cervical squamous cancer cells.
Bai T; Tanaka T; Yukawa K; Umesaki N
Int J Oncol; 2006 Feb; 28(2):497-508. PubMed ID: 16391806
[TBL] [Abstract][Full Text] [Related]
14. Association of steroid and xenobiotic receptor (SXR) and multidrug resistance 1 (MDR1) gene expression with survival among patients with invasive bladder carcinoma.
Rioja J; Bandrés E; Rosell Costa D; Rincón A; López I; Zudaire Bergera JJ; García Foncillas J; Gil MJ; Panizo A; Plaza L; Rioja LA; Berián Polo JM
BJU Int; 2011 Jun; 107(11):1833-8. PubMed ID: 20840328
[TBL] [Abstract][Full Text] [Related]
15. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
16. Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice.
Zhang Y; Xu F; Liang H; Cai M; Wen X; Li X; Weng J
Oncol Rep; 2016 Mar; 35(3):1340-8. PubMed ID: 26648451
[TBL] [Abstract][Full Text] [Related]
17. Targeting RNF8 effectively reverses cisplatin and doxorubicin resistance in endometrial cancer.
Yang B; Ke W; Wan Y; Li T
Biochem Biophys Res Commun; 2021 Mar; 545():89-97. PubMed ID: 33548629
[TBL] [Abstract][Full Text] [Related]
18. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK
Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814
[TBL] [Abstract][Full Text] [Related]
19. MCL-1 dependency of cisplatin-resistant cancer cells.
Michels J; Obrist F; Vitale I; Lissa D; Garcia P; Behnam-Motlagh P; Kohno K; Wu GS; Brenner C; Castedo M; Kroemer G
Biochem Pharmacol; 2014 Nov; 92(1):55-61. PubMed ID: 25107702
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer.
Nakamura M; Kyo S; Zhang B; Zhang X; Mizumoto Y; Takakura M; Maida Y; Mori N; Hashimoto M; Ohno S; Inoue M
Hum Pathol; 2010 Nov; 41(11):1516-29. PubMed ID: 20800872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
